重组人p53腺病毒联合放化疗治疗局部晚期非小细胞肺癌  

Treatment of Local Advanced Non-small Cell Lung Cancer with Recombinant Human p53 Adenovirus Combined with Radiochemotherapy

作　　者：王建功[1] 王晓红[2] 杨俊泉[2] 李国欢 胡万宁[1] 

机构地区：[1]唐山市肿瘤医院生物治疗科,河北唐山063000 [2]唐山市肿瘤医院放化疗科,河北唐山063000

出　　处：《贵阳医学院学报》2014年第2期225-228,共4页Journal of Guiyang Medical College

基　　金：河北省卫生厅医学科学研究重点课题计划资助项目(2011-0196)

摘　　要：目的：探讨重组人p53腺病毒（rAd-p53）基因联合放化疗治疗局部晚期非小细胞肺癌（NSCLC）的疗效及安全性.方法：64例Ⅲ期NSCLC患者,随机分为A组31例（rAd-p53＋放化疗）,B组33例（放化疗）;A组采用3支rAd-p53用10 mL生理盐水稀释,缓慢进行支气管动脉灌注,共灌注2次;3 d后,A、B组同步放化疗,放疗为60Gy/30F;化疗采用PE化疗方案,第1、8、29、36天给顺铂50 mg/m2,第1～5、29～33天给足叶已甙50mg/m2.结果：A组、B组有效率分别为70.97％和45.45％,两组比较差异有统计学意义（P＜0.05）;A组患者1年生存率、放射性肺炎、放射性食管炎发生率分别为74.19％ （23/31）、41.94％（13/31）、67.74％（21/31）;B组患者1年生存率、放射性肺炎、放射性食管炎发生率分别为69.70％（23/33）、39.39％（13/33）、69.70％（23/33）,两组比较差异均无统计学意义（P＞0.05）.结论：重组人p53腺病毒联合放化疗提高了局部晚期NSCLC的近期疗效,且未增加放射性肺炎及放射性食管炎发生率.Objective：To explore the curative efficacy and safety of recombinant human adenovirus （rAd-p53） combined with radiochemotherapy in treating local advanced non-small cell lung cancer （NSCLC）. Methods： Sixty four cases with local advanced NSCLC were randomly divided into. rAd- p53 combined with radiochemotherapy treating group （group A）, radiochemotherapy group （group B）. Group A： three rAd-p53 were diluted with 10 mL normal saline and slowly infused to bronchial artery for 2 times. In the three days after infusion, the two groups were accepted radiochemotherapy. Radiotherapy programs ： 60 Gy/30f. Chemotherapy programs ： PE method , giving 50 mg/m2 cisplatin on the 1~t, 8th, 29th, 36th days and 50 mg/m2 etoposide from the 1＇t day to the 5＇h day and from the 29th to the 33th day. Results： The effective rates were 70.97% and 45.45% in group A and B respec- tively （ P 〈 0.05 ）. The survival rates in one year, the occurrences of radiation pneumonitis and radia- tion esophagitis were 74.19 % （23/31）, 41.94 % （ 13/31 ） and 67.74% （21/31） respectively in group A and were 69.70 % （23/33）, 39.39 % （13/33）, 69.70 % （23/33） in group B, there were not statistical differences between the two groups （ P 〉 0.05 ）. Conclusions： rAd-p53 combined with radiochemotherapy can improve the short-term effects in treating local advanced NSCLC with out increasing adding radiation pneumonitis and radiation esophagitis rates.

关 键 词：癌 非小细胞肺 重组人P53腺病毒 化疗 放射疗法 基因治疗 

分 类 号：R734.2[医药卫生—肿瘤]